While heart disease, diabetes and prediabetes are the most common health concerns related to obesity, many other conditions ...

While this coincides with an uptick in GLP-1 drug use, some experts told Newsweek they don't think they are having a major ...

Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder ...

Obesity among adults continues to be a major public health issue in the United States and other economically developed countries, according to the Centers for Disease Control and Prevention (CDC) and ...

Explore Zepbound's "Changing the Threads" exhibit, which is redefining the stigma of obesity through powerful stories and ...

Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.

Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on ...

The potential disadvantages of drugs increasingly used by patients to achieve greater weight loss are often not highlighted ...

Hypothalamic obesity (HyOb) is a type of obesity caused by damage to the brain’s hunger-regulating function. While there’s no cure, proper treatment can help improve your daily life and prevent ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Obesity severity is incrementally associated with a broad range of cardiometabolic and renal disease burden, as discovered by ...

Taxpayers subsidize ultra-processed calories through SNAP, the resulting disease through Medicare and Medicaid, and then ...